Revolution Medicines heads into its June 18 Q1 results with the Street's conviction rising and short sellers quietly rebuilding positions after a month of covering.
The analyst story is the dominant theme this week. Targets have moved sharply higher across the board, with Evercore ISI lifting its price objective to $220 from $200 just today — the most aggressive call in the current consensus. RBC Capital, Oppenheimer, and HC Wainwright all raised targets in the past two weeks, clustering in the $182–$195 range. Bernstein's fresh initiation at Market Perform with a $151 target is the lone dissenting voice, sitting almost exactly at the current price of $149.55 and signalling that at least one new entrant views upside as priced in. The mean Street target of $187 implies around 25% upside from here — a meaningful premium, though not extreme for a clinical-stage oncology name that has rallied 5% over the past month. Sixteen of the analysts tracked have a buy-equivalent rating, with no sell coverage visible in the data.
The positioning picture is less charged than the analyst enthusiasm suggests. Short interest has ticked back up roughly 3.6% over the past week to 6.1% of free float — after falling 14% over the prior month. That rebound brings shorts back toward 11.9 million shares, recovering some ground lost when the stock rallied through May. Critically, the borrow market shows no stress: availability is extraordinarily loose at 3,033% — meaning there are more than thirty shares available to borrow for every one already lent out — and the cost to borrow has actually fallen 15% on the week to a low 0.39%. That is not the profile of a crowded or squeezed short position. The ORTEX short score of 42.4 sits near the middle of the range, consistent with a modest, rebuilding short book rather than any directional conviction.
Options positioning has shifted meaningfully calmer than it was six weeks ago. The put/call ratio now runs at 1.0, almost exactly in line with its 20-day average of 1.06 and well below the 1.35 readings seen in late April and early May. That shift — from defensive toward neutral — aligns with a market that has largely shed its post-selloff hedges. The 52-week PCR range of 0.16 to 2.23 shows how wide the sentiment swings can be for RVMD; the current reading is notably calm relative to that history.
The bull case rests on RVMD's position as a leading developer of RAS inhibitors — a class targeting one of oncology's most intractable mutation profiles — with a pipeline that the Street increasingly believes can differentiate on both efficacy and safety. Bears point to the pre-revenue stage, deeply negative earnings yield, and the risk that daraxonrasib faces pricing and adoption headwinds even if approved. The EV/EBITDA multiple of -19.9 and price-to-book of 16.7 reflect a company priced on future optionality rather than current fundamentals — the analyst recommendation differential factor score of 92 underscores how far above the broader market RVMD sits on Street conviction. Insider data adds a mild cautionary note: net selling of around $29 million in the 90 days to late May, including a $18 million sale by CEO Mark Goldsmith in April, is worth noting even if the trade significance scores are low and the volumes are modest relative to the float.
RVMD's two most recent earnings releases both produced negative next-day moves — down 6.1% in May and down 3.2% the prior quarter — before recovering into a positive five-day return. With the June 18 print approaching, the next read is less about whether the pipeline is progressing and more about whether any data updates or guidance language can sustain the target upgrades that have arrived almost weekly throughout May and June.
See the live data behind this article on ORTEX.
Open RVMD on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
